Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.

Menghui LuoXiaocen KongHuiying WangXiaofang ZhaiTingting CaiBo DingYun HuTing JingXiaofei SuHui-Qin Li Jian-Hua Ma

Published in: Journal of diabetes research (2020)

Dapagliflozin may reduce blood glucose levels, ameliorate glycemic variability, and improve pancreatic beta-cell function in patients with T2D under insulin glargine combined with other oral hypoglycemic drugs, especially in those with poor glucose control and abdominal obesity.

Keyphrases

glycemic control
blood glucose
type diabetes
weight loss
insulin resistance
metabolic syndrome
high fat diet induced
weight gain
body mass index